Hyderabad, Feb. 25 (PTI): The attorney generals of Texas and California have separately sought information on the pricing of some drugs sold by Dr Reddy’s Laboratories in the US, according to the latest filing of the drug maker with the US Securities and Exchange Commission (SEC).
The development comes after two members of United States Congress wrote to the company, requesting information and expressing “concern” over the “escalating prices” of two products – divalproex sodium ER and pravastatin sodium – marketed by it in the US.
On or about November 10, 2014, DRL received a civil investigative demand (CID) from the office of the Attorney General, State of Texas, requesting certain information for the period between January 1, 1995, and the date of the CID.
Similarly, on November 3, 2014, the drug maker received a subpoenato appear before the office of the Attorney General, California, and produce documents relating to the pricing of 15 products, the filing said.
Data demand
“The CID includes a broad range of requests for information, documents and data regarding sales and price reporting in the US marketplace of certain products.
“We communicated with the Texas AG, at which time they requested a sample of certain transactional data pertaining to one calendar quarter requested in the CID, and agreed to provide such sample transactional data to the Texas AG no later than February 20, 2015,” DRL said in the filing.
A DRL official confirmed the developments, but refused to divulge more details.
“We confirm having received the CID. We are working closely with the office of the Attorney General, Texas, in responding to their queries so as to expedite a speedy redress to the information they have sought from us,” a DRL official said.
via NorthEast Calling http://ift.tt/1BfW1mJ
No comments:
Post a Comment